HUE047062T2 - Angiotenzin II alacsony vérnyomás kombinációs kezelésére - Google Patents

Angiotenzin II alacsony vérnyomás kombinációs kezelésére

Info

Publication number
HUE047062T2
HUE047062T2 HUE14872684A HUE14872684A HUE047062T2 HU E047062 T2 HUE047062 T2 HU E047062T2 HU E14872684 A HUE14872684 A HU E14872684A HU E14872684 A HUE14872684 A HU E14872684A HU E047062 T2 HUE047062 T2 HU E047062T2
Authority
HU
Hungary
Prior art keywords
hypotension
angiotensin
treatment
combination
Prior art date
Application number
HUE14872684A
Other languages
English (en)
Hungarian (hu)
Inventor
Lakhmir Chawla
Original Assignee
The George Washington Univ A Congressionally Chartered Not For Profit Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53367119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE047062(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The George Washington Univ A Congressionally Chartered Not For Profit Corporation filed Critical The George Washington Univ A Congressionally Chartered Not For Profit Corporation
Publication of HUE047062T2 publication Critical patent/HUE047062T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/085Angiotensins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE14872684A 2013-12-18 2014-12-18 Angiotenzin II alacsony vérnyomás kombinációs kezelésére HUE047062T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361917576P 2013-12-18 2013-12-18
US201461955706P 2014-03-19 2014-03-19

Publications (1)

Publication Number Publication Date
HUE047062T2 true HUE047062T2 (hu) 2020-04-28

Family

ID=53367119

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14872684A HUE047062T2 (hu) 2013-12-18 2014-12-18 Angiotenzin II alacsony vérnyomás kombinációs kezelésére

Country Status (25)

Country Link
US (7) US9220745B2 (enExample)
EP (2) EP3607962B1 (enExample)
JP (4) JP6824739B2 (enExample)
KR (4) KR20220028125A (enExample)
CN (4) CN106061493A (enExample)
AU (3) AU2014364528C1 (enExample)
BR (1) BR112016013961A2 (enExample)
CA (1) CA2933601A1 (enExample)
CY (1) CY1122604T1 (enExample)
DK (2) DK3607962T3 (enExample)
EA (1) EA037823B1 (enExample)
ES (1) ES2771749T3 (enExample)
FI (1) FI3607962T3 (enExample)
HR (1) HRP20200009T1 (enExample)
HU (1) HUE047062T2 (enExample)
IL (1) IL246162B (enExample)
LT (1) LT2986308T (enExample)
MX (2) MX380968B (enExample)
NZ (1) NZ721089A (enExample)
PL (1) PL2986308T3 (enExample)
PT (2) PT3607962T (enExample)
RS (1) RS59804B1 (enExample)
SI (1) SI2986308T1 (enExample)
SM (1) SMT202000018T1 (enExample)
WO (1) WO2015095535A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
BR112016013961A2 (pt) 2013-12-18 2017-10-10 The George Washington Univ A Congressional Chartered Not For Profit Corporation angiotensina ii sozinha ou em combinação para o tratamento da hipotensão
TW202214219A (zh) * 2014-07-08 2022-04-16 美商拉荷亞製藥公司 治療低血壓之方法
WO2016153558A1 (en) 2015-03-20 2016-09-29 Atkinson Arthur J Use of angiotensin ii (aii) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps
EP3400001A1 (en) * 2016-01-07 2018-11-14 La Jolla Pharmaceutical Company Methods of administering vasopressors
TW201733610A (zh) 2016-01-07 2017-10-01 拉荷亞製藥公司 投與血管收縮素ii之方法
WO2018191678A1 (en) * 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
US20190183962A1 (en) * 2017-12-15 2019-06-20 La Jolla Pharma, Llc Angiotensin compositions and methods related thereto
WO2023244552A1 (en) * 2022-06-15 2023-12-21 Virginia Commonwealth University Methods for fluid resuscitation of an organ donor
JP2025538841A (ja) * 2022-12-12 2025-11-28 プロレタリアート セラピューティクス, インコーポレイテッド 心損傷を処置する方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU181008B (en) 1980-01-18 1983-05-30 Richter Gedeon Vegyeszet Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position
US5216025A (en) * 1989-09-13 1993-06-01 Board Of Regents, The University Of Texas System Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
EP1401864A1 (en) 2001-06-04 2004-03-31 Human Genome Sciences Methods and compositions for modulating ace-2 activity
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
NO20034952D0 (no) 2003-11-06 2003-11-06 Amersham Health As Farmasöytiske forbindelser
EP1699495A2 (en) 2003-11-06 2006-09-13 Amersham Health AS Conjugates of angiotensin ii and an imaging moiety
FR2880807B1 (fr) * 2005-01-19 2007-04-13 Aguettant Sa Lab Composition pharmaceutique injectable
WO2007040636A1 (en) 2005-09-29 2007-04-12 Fibrogen, Inc. Methods for reducing blood pressure
US20090304818A1 (en) 2005-12-30 2009-12-10 May Clive N Method of treatment
CA2655144A1 (en) 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
CN101795675A (zh) 2006-11-17 2010-08-04 达沃尔泰拉公司 使用具有Eudragit包衣的Zn/果胶珠粒进行的结肠递送
WO2009009907A1 (en) * 2007-07-18 2009-01-22 The University Of British Columbia Use of vasopressin-receptor agonists for the treatment of septic shock
EP2161030A1 (en) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
AU2009319856A1 (en) 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
FR2959414B1 (fr) * 2010-04-30 2016-01-08 Luc Quintin Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
BR112013000744A2 (pt) 2010-07-14 2020-07-14 Cumberland Emerging Technologies, Inc uso de um antagonista de receptor de tromboxana a2 para prevenção ou tratamento de síndrome hepatorrenal,encefalopatia hepática,e doenças associadas
JP6522584B2 (ja) 2013-04-26 2019-05-29 ラ ホヤ ファーマシューティカル カンパニーLa Jolla Pharmaceutical Company 腎不全を処置するための組成物及び方法
BR112016013961A2 (pt) 2013-12-18 2017-10-10 The George Washington Univ A Congressional Chartered Not For Profit Corporation angiotensina ii sozinha ou em combinação para o tratamento da hipotensão
US20150286797A1 (en) 2014-04-02 2015-10-08 David R. Ratto System and method for administering medication
TW202214219A (zh) 2014-07-08 2022-04-16 美商拉荷亞製藥公司 治療低血壓之方法
EP3400001A1 (en) 2016-01-07 2018-11-14 La Jolla Pharmaceutical Company Methods of administering vasopressors
TW201733610A (zh) 2016-01-07 2017-10-01 拉荷亞製藥公司 投與血管收縮素ii之方法
WO2018191678A1 (en) 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
US20190183962A1 (en) 2017-12-15 2019-06-20 La Jolla Pharma, Llc Angiotensin compositions and methods related thereto

Also Published As

Publication number Publication date
LT2986308T (lt) 2020-03-25
EA037823B1 (ru) 2021-05-25
EP3607962B1 (en) 2025-08-13
PT2986308T (pt) 2020-01-21
KR20220028125A (ko) 2022-03-08
WO2015095535A9 (en) 2016-07-14
JP6824739B2 (ja) 2021-02-03
JP2025114753A (ja) 2025-08-05
JP2017501154A (ja) 2017-01-12
US10028995B2 (en) 2018-07-24
US20190328827A1 (en) 2019-10-31
SMT202000018T1 (it) 2020-03-13
RS59804B1 (sr) 2020-02-28
US11559559B2 (en) 2023-01-24
DK2986308T3 (en) 2020-01-27
US20230226141A1 (en) 2023-07-20
JP7175506B2 (ja) 2022-11-21
BR112016013961A2 (pt) 2017-10-10
US10493124B2 (en) 2019-12-03
AU2020277230A1 (en) 2020-12-24
NZ721089A (en) 2022-10-28
CN112546197A (zh) 2021-03-26
JP2022137224A (ja) 2022-09-21
CN111920939A (zh) 2020-11-13
US10765722B2 (en) 2020-09-08
KR20230051721A (ko) 2023-04-18
KR20240154702A (ko) 2024-10-25
EP3607962A1 (en) 2020-02-12
US20150164980A1 (en) 2015-06-18
HRP20200009T1 (hr) 2020-03-20
JP2019214610A (ja) 2019-12-19
CN106061493A (zh) 2016-10-26
DK3607962T3 (da) 2025-11-17
AU2014364528A9 (en) 2016-07-28
EP2986308A1 (en) 2016-02-24
MX2016008108A (es) 2017-03-09
KR102399383B1 (ko) 2022-05-19
PL2986308T3 (pl) 2020-05-18
PT3607962T (pt) 2025-11-18
EP2986308B1 (en) 2019-10-16
CA2933601A1 (en) 2015-06-25
AU2014364528A1 (en) 2016-06-30
CN119700926A (zh) 2025-03-28
AU2014364528C1 (en) 2021-01-07
IL246162A0 (en) 2016-07-31
EP2986308A4 (en) 2017-01-11
SI2986308T1 (sl) 2020-03-31
FI3607962T3 (fi) 2025-11-24
AU2014364528B2 (en) 2020-08-27
US20160129072A1 (en) 2016-05-12
US9220745B2 (en) 2015-12-29
EA201691258A1 (ru) 2016-11-30
ES2771749T3 (es) 2020-07-07
KR20160117437A (ko) 2016-10-10
MX2020011190A (es) 2020-11-13
IL246162B (en) 2020-03-31
US20220047669A1 (en) 2022-02-17
MX380968B (es) 2025-03-12
US20190070250A1 (en) 2019-03-07
WO2015095535A1 (en) 2015-06-25
AU2024219851A1 (en) 2024-10-10
US11096983B2 (en) 2021-08-24
US20180193407A1 (en) 2018-07-12
CY1122604T1 (el) 2021-03-12

Similar Documents

Publication Publication Date Title
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
PL3542798T3 (pl) Aceklidyna do zastosowania w leczeniu starczowzroczności
GB201321743D0 (en) Therapeutic agents
GB201321746D0 (en) Therapeutic agents
GB201321738D0 (en) Therapeutic Agents
GB201321736D0 (en) Therapeutic agents
GB201321729D0 (en) Therapeutic agents
GB201321728D0 (en) Therapeutic agents
GB201321733D0 (en) Therapeutic agents
GB201321739D0 (en) Therapeutic agents
GB201321730D0 (en) Therapeutic agents
GB201321741D0 (en) Therapeutic agents
GB201321740D0 (en) Therapeutic agents
IL246162A0 (en) Angiotensin II, alone or in combination, to treat low blood pressure
GB201321732D0 (en) Therapeutic agents
GB201321734D0 (en) Therapeutic Agents
GB201321744D0 (en) Therapeutic agents
GB201321737D0 (en) Therapeutic Agents
GB201321742D0 (en) Therapeutic agents
GB201321748D0 (en) Therapeutic agents
GB201321735D0 (en) Therapeutic Agents
GB201321745D0 (en) Therapeutic agents
GB201321731D0 (en) Therapeutic agents
GB201304872D0 (en) Treatment
GB201321749D0 (en) Therapeutic agents